Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer
Written by Emily J. Thompson, Senior Investment Analyst
Source: Newsfilter
Acquisition Details: Carlyle, SK Capital, and Beacon Parent Holdings have successfully completed the tender offer to acquire bluebird bio, with the acquisition expected to finalize on June 2, 2025, after 59.8% of shares were validly tendered.
Company Background: bluebird bio is a leader in gene therapy focused on severe genetic diseases, having secured FDA approvals for three therapies and aiming to deliver innovative solutions while maintaining a commitment to patient communities.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
